Real-World Chinese Study of the Effectiveness and Safety of Switching From Dupilumab to Stapokibart in Patients With Moderate-to-Severe Atopic Dermatitis

Background: Some patients with atopic dermatitis (AD) have an inadequate response or intolerance to dupilumab. Stapokibart, a novel anti-IL-4Rα antibody, is a potential alternative. Objective: To assess the real-world effectiveness and safety of switching from dupilumab to stapokibart in moderate-to-severe AD. Methods: This retrospective study included 85 patients (67 mild and 18 moderate-to-severe after dupilumab) who switched to stapokibart for ≥16 weeks. Efficacy and safety were evaluated over 16 weeks. Results: Stapokibart led to rapid and significant improvements in all patients. By week 16, the Eczema Area and Severity Index (EASI) scores dramatically decreased, and high rates of EASI-90 (89.6% mild and 88.9% moderate-to-severe) were achieved. The mild group showed faster and deeper remission (e.g., EASI-100: 71.6% vs 50.0%). Disease control and quality of life improved significantly. The most common adverse event (AE) was injection site reaction (2.4%); no serious AEs or discontinuations occurred. Conclusion: Switching to stapokibart is an effective and safe strategy for patients with an inadequate response to dupilumab, inducing rapid and profound clinical improvement. It is a valuable sequential treatment for AD.